Tools
Orlistat
Indications
Orlistat (tetrahydrolipstatin) is an anti-obesity medication approved by the US Food and Drug Administration (FDA). This medication is a saturated derivative derived from the endogenous lipstatin found in Streptomyces toxytricini.
FDA-Approved Indications
The FDA-approved indication of orlistat include:
- Patients with obesity with a body mass index (BMI) of over 30 kg/m2.
- Patients with a BMI greater than 27 kg/m2 and the presence of risk factors, including hypertension, diabetes, and dyslipidemias.
- Individuals seeking to mitigate the risk of weight regain following previous weight loss efforts.
The maximum benefit of orlistat is achieved when it is combined with a balanced diet and regular exercise. Weight reduction typically begins within 2 weeks of initiating orlistat. Statistically significant weight loss is observed after orlistat use exceeds 2 months.[1] The mean weight loss in patients by the end of 6 months of orlistat use is approximately 5.6 kg, whereas those in the placebo group show a weight loss of only 2.4 kg.
Orlistat also leads to notable reductions in BMI, waist circumference, total cholesterol, and low-density lipoprotein levels.[2][3] In the XENDOS trial, orlistat demonstrates a statistically significant effect in reducing the incidence of diabetes among patients with impaired glucose tolerance.[4] The American Association of Pediatrics guidelines recommend orlistat for managing obesity in children aged 12 and older.[5]
Off-Label Uses
According to a scientific statement from the American Heart Association (AHA) in 2021, orlistat is deemed safe and effective for treating obesity in individuals with heart failure.[6] In addition, a study reported that orlistat is safe and effective in lowering serum triglycerides in children with type 1 hyperlipoproteinemia.[7] Furthermore, a systematic review and meta-analysis suggest that orlistat may offer efficacy in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), showing improvements in specific biomarkers. However, the reversal of liver fibrosis appears inconsistent, with findings limited by data scarcity and variable results, rendering definitive conclusions challenging.
Although orlistat may enhance biochemical markers, it is not the primary recommendation for NAFLD/NASH. Larger-scale studies evaluating additional liver parameters over an extended duration are essential to provide more precise insights.[8]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Orlistat reversibly inhibits gastric and pancreatic lipases, which play a crucial role in the digestion of dietary fat. Lipase breaks down triglycerides into absorbable free fatty acids and monoglycerides. Orlistat covalently binds to the serine residues of the active sites of lipases, rendering them inactive. This inactivation prevents triglyceride hydrolysis, leading to a reduction in the absorption of free fatty acids.[9]
The primary action of orlistat is localized lipase inhibition within the gut, rendering systemic absorption unnecessary for its activity. Orlistat inhibits dietary fat absorption by approximately 30% at the recommended dosage. According to the AHA, this percentage change in weight is also associated with a slight reduction in blood pressure.[10]
Research also indicated that orlistat has a beneficial consequence on carbohydrate metabolism.[11] Furthermore, as obesity heightens the risk of hyperuricemia and cardiovascular disease, meta-analysis results have shown that orlistat significantly lowers serum uric acid levels in adult patients.[12]
Pharmacokinetics
Absorption: Orlistat primarily exerts its effects locally in the gut, resulting in minimal systemic exposure to the medication.
Distribution: Most of the drug (over 99%) binds to plasma proteins, with lipoproteins and albumin being the primary binding proteins.
Metabolism: Orlistat undergoes primary metabolism within the intestinal wall.
Elimination: Approximately 95% to 97% of the medication is unabsorbed and excreted in feces.[13]
Administration
Available Dosage Forms and Strengths
Orlistat is available in oral tablet formulations, with strengths of 60 mg (available over the counter) and 120 mg (prescription product).
Adult Dosage
The recommended orlistat prescription dosage is 120 mg capsule orally thrice daily. The administration is during or within 1 hour after the fat-containing meal. The dosage of more than 120 mg/d has no additional benefit. The recommendation is that the patient adheres to a nutritionally balanced, low-calorie diet with less than 30% of calories from fat.
If the patient misses the meal, they can omit the orlistat dose. If the patient misses the dose of orlistat and it has been more than 2 hours past the fat-containing meal, then the patient can skip that dose since, by that time, most of the fat absorption has already occurred, and the medication would not work effectively. Since orlistat reduces the absorption of fat-soluble vitamins, patients should take multivitamin supplements (containing fat-soluble vitamins) daily. Administration of multivitamin supplements should be at a gap of more than 2 hours after the orlistat administration.[14]
Specific Patient Populations
Renal impairment: Orlistat is considered safe for use in patients with renal impairment.
Hepatic impairment: Caution is advised when prescribing orlistat to patients with obstructed bile ducts and abnormal liver function tests.[15]
Pregnancy considerations: Orlistat is contraindicated during pregnancy, as it was previously classified as an FDA pregnancy category X drug. Patients undergoing orlistat therapy should receive counseling regarding the importance of contraception. The United States Preventive Services Task Force (USPTSF) recommends that limiting gestational weight gain during pregnancy is associated with a decreased risk of emergency cesarean delivery, gestational diabetes mellitus, and macrosomia. Behavioral interventions are preferred over pharmacotherapy for managing gestational weight gain.[16][17][18]
Breastfeeding considerations: Orlistat is minimally absorbed in the body, with only a small amount detected in breast milk. However, orlistat inhibits the absorption of fat-soluble vitamins, so breastfeeding mothers should take a multivitamin supplement containing these vitamins. Infants are unlikely to absorb orlistat in quantities that would negatively affect them.[19] Nonetheless, manufacturer labeling advises caution when orlistat is used during lactation and clinical practice guidelines do not recommend weight-management medications while breastfeeding.[20]
Pediatric patients: Orlistat is FDA-approved for long-term treatment of obesity in children aged 12 and older.[5][21] However, the safety and efficacy of orlistat have not been established in pediatric patients aged 12 or younger.
Older patients: Studies have indicated the efficacy of orlistat in the older patient population.[1] Orlistat is FDA-approved in older patients with obesity.[22]
Adverse Effects
Adverse Effects
The adverse effects of orlistat include the following:
Gastrointestinal: The most common adverse effect of orlistat use is steatorrhea, which occurs because of the impaired absorption of dietary fat. Other adverse effects include fecal spotting, diarrhea, abdominal pain, and anal fissures. The gastrointestinal adverse effects decrease with orlistat therapy. These adverse effects can be minimized by following a hypocaloric and low-fat diet with less than 30% of the calories from fats.[11] Rarely, orlistat correlates with cholelithiasis, pancreatitis, and acute cholestatic hepatitis. However, orlistat reverses steatosis in patients with NAFLD.[8] Orlistat inhibits the absorption of fat-soluble vitamins and other fat-soluble nutrients. Patients should use a multivitamin tablet containing vitamins A, D, E, K, and beta-carotene once daily.[23]
Hepatotoxicity: Cases of hepatotoxicity range from serum enzyme elevations to a few cases of fatal hepatic failure and the requirement for emergency liver transplantation. The proposed mechanism for hepatotoxicity is hypersensitivity, as only a small amount of orlistat is absorbed. However, clinical features of hypersensitivity are absent in orlistat-induced hepatotoxicity.[15]
Musculoskeletal: Theoretically, orlistat can increase the risk of osteoporosis because of impaired absorption of calcium and vitamin D.
Oncology: Animal studies have shown an increased risk of colorectal cancer with orlistat. However, in humans, no such association has been elucidated. Orlistat inhibits the synthesis of fatty acid synthase (Fas) enzyme, which increases tumor growth. In addition, orlistat has anti-neoplastic activity in various animal studies in ovarian, breast, and prostate cancer cells. Few case reports have illustrated the association of orlistat use with hypertension, diabetic ketoacidosis, depression, cutaneous vasculitis, lichenoid eruptions, and vaginitis. However, a causal relationship between orlistat and these adverse effects remains unproven.
Drug-Drug Interactions[11]
- Antiepileptics: Orlistat can reduce the absorption of lipophilic antiepileptics like lamotrigine, valproate, vigabatrin, and gabapentin, resulting in a decrease in plasma concentration. In such cases, it is recommended to monitor antiepileptic medication levels.[24]
- Amiodarone: Orlistat can reduce the absorption of amiodarone.[25]
- Cyclosporine: Orlistat can also reduce the absorption of cyclosporine (immunosuppressant). Therefore, the recommendation is to administer these 2 medications at a gap of at least 3 hours. Also, the cyclosporine levels require monitoring in patients taking the medication along with orlistat.[26][27]
- Levothyroxine: Orlistat can bind with levothyroxine in the gut and reduce its absorption, leading to decreased plasma concentration of levothyroxine and subsequent hypothyroidism. Thus, clinicians should advise patients to take levothyroxine and orlistat at least 4 hours apart.[28]
- Warfarin: Using orlistat and warfarin can result in prolonged prothrombin time and INR because orlistat reduces the absorption of vitamin K. Therefore, coagulation parameters require monitoring in patients taking these medications together.[29]
- Antiretroviral medications: Orlistat also reduces the absorption of antiretroviral drugs; monitoring of HIV viral load is necessary. If the HIV viral load increases, orlistat should be discontinued.[30]
Contraindications
Box Warnings
Orlistat is contraindicated in individuals with hypersensitivity to Orlistat or its constituents, cholestasis, pregnancy, and chronic malabsorption.[31][32]
Warning and Precautions
- Orlistat can increase the risk of acute kidney injury. This happens because undigested fat binds with calcium in the intestine, producing excess oxalate. This oxalate is absorbed by the body and deposited in the kidney, which increases the risk of renal stones.[33]
- Orlistat should be used with caution in patients with anorexia or bulimia nervosa.[34]
- Healthcare professionals must rule out organic causes of obesity like hypothyroidism or Cushing syndrome before initiating orlistat therapy.[35]
Monitoring
Below are suggestions to monitor patients on orlistat:
- Monitoring the body weight, BMI, waist circumference, and lipid profile of patients taking orlistat is necessary.
- The levels of cyclosporine, antiepileptics, and HIV viral load require monitoring when using orlistat in conjunction with these medications.[11]
- Patients with diabetes might need to adjust the dose of diabetes medicine, as weight loss can affect glycemic control.
- Monitor the impact of Weight loss on Quality of Life-Lite (IWQOL-Lite), a widely used tool in assessing weight-loss interventions in clinical trials.[36]
- According to the American Association of Clinical Endocrinologists (AACE) Medical Guidelines for Clinical Practice/American College of Endocrinology guidelines (ACE), patients receiving orlistat should be monitored for cholelithiasis in patients with mild hepatic impairment. In patients receiving orlistat, a risk of nephrolithiasis is apparent; monitor for flank pain and hematuria.[37]
Toxicity
Signs and Symptoms of Overdose
No specific antidote for orlistat overdose is available. However, if a significant overdose of orlistat occurs, the patient should immediately go to the emergency department and be observed for 24 hours to provide supportive care.
Management of Overdose
In a study involving 105 pediatric patients, orlistat exposures among young children were managed by decontamination and had favorable outcomes with few gastrointestinal adverse clinical effects.[38]
Enhancing Healthcare Team Outcomes
Obesity and its comorbidities have a significant burden on the healthcare system. According to AHA, obesity is a multifactorial disease that leads to adverse health outcomes. Obesity is linked to dyslipidemia, type II diabetes, hypertension, and sleep disorders. Obesity is also associated with increased coronary artery calcium score, a marker of coronary atherosclerosis. Obesity leads to cardiovascular disease and mortality independent of other risk factors.[6] Utilizing pharmacotherapy in the form of orlistat can reduce morbidity and mortality from obesity-related complications.
Orlistat effectively lowers body weight, BMI, cholesterol levels, and waist circumference. It has also been shown to cause a modest decrease in blood pressure and improved glycemic control in patients with diabetes. Gastrointestinal adverse effects are the most common reason for discontinuation of the medication. The drug can be used in the proper clinical setting to achieve weight loss goals and decrease obesity complications.
Clinicians must be vigilant while prescribing orlistat, especially in patients with diabetes, epilepsy, HIV, and blood coagulation disorder. The clinical nurse is required to assist the medical team in educating the patient on the expected gastrointestinal effects of the drug. A specialized pharmacist is key to optimizing therapy with this drug. The pharmacist should assist the medical team in adjusting doses or timing of other medications when starting the patient on orlistat therapy to ensure the efficacy is not reduced.
Dieticians should be involved in patient care, ensuring the patient has direction on a nutritionally balanced, low-calorie diet. Surgical consultation may be required for the management of cholelithiasis or nephrolithiasis. Psychiatrist and psychologist consultations may be necessary for bulimia nervosa. A coordinated and collaborative interprofessional team of clinicians, pharmacists, nurses, physician assistants, and dieticians can improve the efficacy of orlistat therapy and achieve optimal patient results. According to the AACE/ACE comprehensive clinical practice guidelines for obesity, interprofessional collaboration is essential for effectively managing patients with obesity and improving outcomes related to orlistat therapy.[37]
References
Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian journal of endocrinology and metabolism. 2011 Apr:15(2):99-104. doi: 10.4103/2230-8210.81938. Epub [PubMed PMID: 21731866]
Hollywood A, Ogden J. Taking Orlistat: Predicting Weight Loss over 6 Months. Journal of obesity. 2011:2011():806896. doi: 10.1155/2011/806896. Epub 2010 Nov 11 [PubMed PMID: 21113309]
Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998 Jul 18:352(9123):167-72 [PubMed PMID: 9683204]
Level 1 (high-level) evidenceTorgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes care. 2004 Jan:27(1):155-61 [PubMed PMID: 14693982]
Level 1 (high-level) evidenceHampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, Avila Edwards KC, Eneli I, Hamre R, Joseph MM, Lunsford D, Mendonca E, Michalsky MP, Mirza N, Ochoa ER, Sharifi M, Staiano AE, Weedn AE, Flinn SK, Lindros J, Okechukwu K. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023 Feb 1:151(2):. pii: e2022060640. doi: 10.1542/peds.2022-060640. Epub [PubMed PMID: 36622115]
Level 1 (high-level) evidencePowell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP, American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25:143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22 [PubMed PMID: 33882682]
Patni N, Quittner C, Garg A. Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial. The Journal of clinical endocrinology and metabolism. 2018 Jun 1:103(6):2403-2407. doi: 10.1210/jc.2018-00369. Epub [PubMed PMID: 29659879]
Level 1 (high-level) evidenceWang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomedical reports. 2018 Jul:9(1):90-96. doi: 10.3892/br.2018.1100. Epub 2018 May 22 [PubMed PMID: 29930810]
Level 1 (high-level) evidenceGuerciolini R. Mode of action of orlistat. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 1997 Jun:21 Suppl 3():S12-23 [PubMed PMID: 9225172]
Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, Ma J, Ndumele CE, Schauer PR, Shimbo D, American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension (Dallas, Tex. : 1979). 2021 Nov:78(5):e38-e50. doi: 10.1161/HYP.0000000000000202. Epub 2021 Sep 20 [PubMed PMID: 34538096]
Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug safety. 2008:31(1):53-65 [PubMed PMID: 18095746]
Noori S, Mirzababaei A, Amini MR, Clark CCT, Mirzaei K. Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials. International journal of clinical practice. 2021 Nov:75(11):e14674. doi: 10.1111/ijcp.14674. Epub 2021 Aug 24 [PubMed PMID: 34324762]
Level 1 (high-level) evidenceMcClendon KS, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert opinion on drug safety. 2009 Nov:8(6):727-44 [PubMed PMID: 19998527]
Level 3 (low-level) evidenceHeck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000 Mar:20(3):270-9 [PubMed PMID: 10730683]
. Orlistat. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31644205]
Stang J, Huffman LG. Position of the Academy of Nutrition and Dietetics: Obesity, Reproduction, and Pregnancy Outcomes. Journal of the Academy of Nutrition and Dietetics. 2016 Apr:116(4):677-91. doi: 10.1016/j.jand.2016.01.008. Epub [PubMed PMID: 27017177]
Gill L, Mackey S. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. Journal of women's health (2002). 2021 Jul:30(7):1016-1027. doi: 10.1089/jwh.2020.8683. Epub 2021 Feb 24 [PubMed PMID: 33626287]
US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Simon M, Stevermer J, Tseng CW, Wong JB. Behavioral Counseling Interventions for Healthy Weight and Weight Gain in Pregnancy: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 May 25:325(20):2087-2093. doi: 10.1001/jama.2021.6949. Epub [PubMed PMID: 34032823]
. Orlistat. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000855]
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud'homme D, Salas XR, Rueda-Clausen C, Russell-Mayhew S, Shiau J, Sherifali D, Sievenpiper J, Sockalingam S, Taylor V, Toth E, Twells L, Tytus R, Walji S, Walker L, Wicklum S. Obesity in adults: a clinical practice guideline. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2020 Aug 4:192(31):E875-E891. doi: 10.1503/cmaj.191707. Epub [PubMed PMID: 32753461]
Level 1 (high-level) evidenceChao AM, Wadden TA, Berkowitz RI. The safety of pharmacologic treatment for pediatric obesity. Expert opinion on drug safety. 2018 Apr:17(4):379-385. doi: 10.1080/14740338.2018.1437143. Epub 2018 Feb 7 [PubMed PMID: 29411652]
Level 3 (low-level) evidenceMacMillan M, Cummins K, Fujioka K. What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Obesity science & practice. 2016 Dec:2(4):477-482. doi: 10.1002/osp4.66. Epub 2016 Sep 13 [PubMed PMID: 28090354]
McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 Jul:22(7):814-22 [PubMed PMID: 12126214]
Level 3 (low-level) evidenceBigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat. Epilepsia. 2006 Dec:47(12):2207 [PubMed PMID: 17201727]
Level 3 (low-level) evidenceZhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Journal of clinical pharmacology. 2003 Apr:43(4):428-35 [PubMed PMID: 12723464]
Level 1 (high-level) evidenceNägele H, Petersen B, Bonacker U, Rödiger W. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. European journal of clinical pharmacology. 1999 Nov:55(9):667-9 [PubMed PMID: 10638396]
Level 3 (low-level) evidenceAsberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs. 2003:63(4):367-78 [PubMed PMID: 12558459]
Skelin M, Lucijanić T, Amidžić Klarić D, Rešić A, Bakula M, Liberati-Čizmek AM, Gharib H, Rahelić D. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clinical therapeutics. 2017 Feb:39(2):378-403. doi: 10.1016/j.clinthera.2017.01.005. Epub 2017 Jan 30 [PubMed PMID: 28153426]
MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. The Annals of pharmacotherapy. 2003 Apr:37(4):510-2 [PubMed PMID: 12659605]
Level 3 (low-level) evidenceCope RJ, Fischetti BS, Kavanagh RK, Lepa TM, Sorbera MA. Safety and Efficacy of Weight-Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy. Pharmacotherapy. 2019 Dec:39(12):1204-1215. doi: 10.1002/phar.2342. Epub 2019 Nov 3 [PubMed PMID: 31602703]
Saunders KH, Shukla AP, Igel LI, Kumar RB, Aronne LJ. Pharmacotherapy for Obesity. Endocrinology and metabolism clinics of North America. 2016 Sep:45(3):521-38. doi: 10.1016/j.ecl.2016.04.005. Epub [PubMed PMID: 27519128]
MacConnachie AM. Orlistat (Xenical). Intensive & critical care nursing. 1999 Oct:15(5):298-9 [PubMed PMID: 10808826]
Humayun Y, Ball KC, Lewin JR, Lerant AA, Fülöp T. Acute oxalate nephropathy associated with orlistat. Journal of nephropathology. 2016 Apr:5(2):79-83. doi: 10.15171/jnp.2016.14. Epub 2016 Mar 29 [PubMed PMID: 27152294]
Deb KS, Gupta R, Varshney M. Orlistat abuse in a case of bulimia nervosa: the changing Indian society. General hospital psychiatry. 2014 Sep-Oct:36(5):549.e3-4. doi: 10.1016/j.genhosppsych.2014.05.006. Epub 2014 May 17 [PubMed PMID: 24953260]
Level 3 (low-level) evidenceWilding JPH. Endocrine testing in obesity. European journal of endocrinology. 2020 Apr:182(4):C13-C15. doi: 10.1530/EJE-20-0099. Epub [PubMed PMID: 32061161]
Kolotkin RL, Williams VSL, Ervin CM, Williams N, Meincke HH, Qin S, von Huth Smith L, Fehnel SE. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clinical obesity. 2019 Jun:9(3):e12310. doi: 10.1111/cob.12310. Epub 2019 Apr 16 [PubMed PMID: 30993900]
Level 2 (mid-level) evidenceGarvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016 Jul:22 Suppl 3():1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24 [PubMed PMID: 27219496]
Level 1 (high-level) evidenceForrester MB. Pattern of orlistat exposures in children aged 5 years or less. The Journal of emergency medicine. 2009 Nov:37(4):396-9. doi: 10.1016/j.jemermed.2007.10.052. Epub 2008 Apr 10 [PubMed PMID: 18403165]
Level 2 (mid-level) evidence